摘要
目的观察左卡尼汀对重组人红细胞生成素(r-HuEPO)治疗肾性贫血疗效及不良反应,以探讨其临床价值。方法将36例维持性血液透析患者随机分为治疗组和对照组,每组18例,2组同时于血透后每周给予r-HuEPO100～150U/kg皮下注射,待血红蛋白(Hb)≥110g/L,红细胞压积(Hct)≥30%后减量,维持Hct在30%～35%;治疗组另于每次血透后静脉注射左卡尼汀2.0g,共12周。结果2组患者的Hb、Hct较治疗前明显升高,治疗组优于对照组(P<0.05);治疗组红细胞生成素的每周平均用量较对照组少,2组比较差异有统计学意义(P<0.05)。结论左卡尼汀能显著提高促红细胞生成素治疗肾性贫血的疗效,减少促红细胞生成素的用量,降低不良反应发生率。
Objective Observation of L-carnitine on recombinant human erythropoietin（r-HuEPO） treatment of renal anemia efficacy and adverse reactions,in order to investigate its clinical value. Methods 36 cases of hemodialysis patients were randomly divided into treatment group and control group,each 18 cases. Two groups simultaneously on after hemodialysis were gave r-HuEPO 100 - 150U/kg by subcutaneous injection, until the hemoglobin（Hb） ≥ 110g/L, the hematocrit（Hct）≥ 30% ,beganed to decrement, keeped Hct at 30% - 35% ;The patients in treatment group after dialysis intravenous were gave L- Carnitine 2.0g,totally 12 weeks. Results Hb and Hct in two groups patients were significantly higher than that before treatment, and the treatment group better than the group（P 〈 0.05） ;Treatment group erythropoietin of average weekly consumption less than that in control group, the difference was statistically significant（ P 〈 0.05 ）. Condusion L-carnitine can significantly increase the efficacy what erythropoietin treated renal anemia,reduce the dosage of using erythropoietin and the incidence of adverse reactions.
出处
《临床合理用药杂志》
2010年第4期24-25,共2页
Chinese Journal of Clinical Rational Drug Use
